Effect of ExoBDNF Lactic Acid Bacteria Supplement on Cognitive Functions, Sleep and Psychological
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorSunWay Biotech Co., LTD.
About this trial
This open-label, single-group, pre/post-test clinical study was conducted to investigate whether ExoBDNF probiotic supplementation could improve cognitive ability. It is expected that 40 subjects aged 18 years and above will be recruited, with a target of 30 cases, to take ExoBDNF probiotics for a total of 8 weeks.
Eligibility criteria
Qualifiers
Subjects must be volunteers who are 18 years of age or older, mentally clear and able to communicate.
Subjects who agree to participate in this trial and voluntarily sign the trial consent form.
Disqualifiers
Subjects who are expected to be or have been confirmed to be pregnant (medical history).
Subjects with gallbladder disease, gastrointestinal disease, gout, porphyria, or a history of gastric weight control surgery.
Subjects with high blood pressure (≥160/100 mmHg after resting for 10 minutes) or taking diuretics.
Subjects with heart disease, hepatorenal insufficiency, hyperthyroidism or hypothyroidism, Cushing's syndrome, malignant tumors, or any other disease that may affect the results of the study.
Trial design
Treatments tested in this trial
- ExoBDNF SWP-CGPA01 (Pediococcus acidilactici)Capsules
Treatment groups
50 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov